What's New
Front Page
Perspectives in FTD Research Webinar: FTD Research 2024 – Where We’ve Come From and Where We’re Headed
The science of FTD is evolving at a rapid pace and it can be difficult to interpret…
AFTD Ambassador Advocates on Behalf of the Older Americans Act
AFTD Ambassador Judy Bearer advocated for the reauthorization of the Older Americans Act (OAA) in a December…
Advancing Hope: AFTD Attends 2024 Society for Neuroscience Meeting
Dr. Nicole Bjorklund, AFTD Director of Research and Grants, and Dr. Kate Still, Research Outreach Manager, attended…
New York Software Company Awards AFTD Gift to Honor Employee’s Late Cousin
AFTD has been selected as one of three organizations to receive a gift from Mindex, a software-development…
Transposon Presents Results from Successful Phase 2 ALS/FTD Clinical Trial
Biotechnology company Transposon Therapeutics presented the results from its successful phase 2 clinical trial of its experimental…
AviadoBio CEO Emphasizes Collaborative Approach for Treating FTD
In October, U.K.-based gene therapy company AviadoBio, Ltd., and pharmaceutical company Astellas announced an exclusive option and…
Dear HelpLine: Types of FTD
Dear HelpLine, My mom was recently diagnosed with FTD, and when I visited your website, I learned…
Advancing Hope: AFTD Develops New Gene Therapy Resource
There is more hope now than ever before that researchers will be able to develop a treatment…
Advancing Hope: Sponsored Testing Programs; opportunities for no-cost genetic testing
Once you have chosen to pursue genetic testing, it can be frustrating to learn that the cost…
Ferrer Doses First Participant in Phase 2 Study for PSP Treatment
Pharmaceutical company Ferrer announced that it has dosed the first participant in the PROSPER phase 2 clinical…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)